The Inflammatory Cytokine Network of Epithelial Cancer: Therapeutic Implications

  1. Derek J. Chadwick Organizer,
  2. Jamie A. Goode
  1. Peter Szlosarek,
  2. Fran Balkwill*

Published Online: 7 OCT 2008

DOI: 10.1002/0470856734.ch17

Cancer and Inflammation: Novartis Foundation Symposium 256

Cancer and Inflammation: Novartis Foundation Symposium 256

How to Cite

Szlosarek, P. and Balkwill, F. (2008) The Inflammatory Cytokine Network of Epithelial Cancer: Therapeutic Implications, in Cancer and Inflammation: Novartis Foundation Symposium 256 (eds D. J. Chadwick and J. A. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470856734.ch17

Author Information

  1. Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, John Vane Science Centre, London EC1M 6BQ, UK

*Cancer Research UK, Translational Oncology Laboratory, Barts and The London, Queen Mary's School of Medicine and Dentistry, John Vane Science Centre, London EC1M 6BQ, UK

Publication History

  1. Published Online: 7 OCT 2008
  2. Published Print: 23 JAN 2004

Book Series:

  1. Novartis Foundation Symposia

Book Series Editors:

  1. Novartis Foundation

ISBN Information

Print ISBN: 9780470855102

Online ISBN: 9780470856734

SEARCH

Summary

A network of inflammatory cytokines and chemokines is found in epithelial cancer. There is evidence that these mediators contribute not only to tumour cell growth and survival, but also to communication between the cancer cells and stromal elements. Tumour cell production of the inflammatory cytokine tumour necrosis factor α (TNFα) is one critical factor in this autocrine and paracrine network. TNFα may also initiate and sustain production of other cytokines and chemokines. Chemokines are key determinants of the leukocyte infiltrate in solid ovarian tumours and influence the extent and phenotype of the infiltrate in ascitic disease. Chemokines may also be involved in tumour cell spread. Thus some of the processes involved in chronic inflammation are also active in human epithelial cancers. Agents that antagonize TNFα or chemokines are currently being assessed in preclinical animal cancer models and in phase I clinical trials.